Advanced targeted
therapies for invasive
cancers

About

Breakthrough technology enabling first in class therapies

We develop first-in-class protein-protein interaction antagonists (PPIAs) against invasive cancers. Our breakthrough technology, ACINDA, accelerates drug discovery and enables the precise design of small molecule inhibitors against specific proteins which cause cancer cell invasion. Our first-in-class protein-protein integration antagonists (PPIAs) combine potent anti-tumour activity with a favourable safety profile for patients with invasive cancers.

PRODUCT

F2i: Invasight's first drug development program 

Invasight's first drug development program targets pro-invasive fibroblast growth factor (FGF) signalling in human cancers. Leveraging ACINDA, we have developed 'F2i', a first-in-class, non-kinase, small molecule PPIA of the FGF signalling pathway. Traditionally, FGF signalling pathways are targeted via direct or indirect small molecule kinase inhibitors of Fibroblast growth factor receptors (FGFRs). However, this way of inhibiting FGF signalling causes the development of resistance and off-target-related side effects and toxicities. 

Unlike the traditional FGFR kinase inhibitors, F2i does not target or bind to any FGFRs. Instead, F2i uniquely inhibits the pro-invasive FGF signalling by binding to an exclusive adapter protein downstream of FGF signalling. F2i disrupts the interaction between FGFR and the next effector protein of FGF signalling. This, in turn, prevents phosphorylation and signal transduction to the following proteins in the FGF signalling pathway. Subsequently, this disruption turns off the aberrant pro-invasive and pro-proliferative FGF signalling in cancer cells with reduced side effects and toxicities.

The efficacy, safety and mechanism of action of F2i have been extensively validated using various FGF-driven in vitro and in vivo models. F2i effectively inhibits tumour growth and invasion in different tumour xenograft models. F2i is currently in the 'lead optimisation' stage of drug development. 

PIPELINE

Invasight’s Pipeline

Our first-in-class protein-to-protein interaction antagonists (PPIAs) combine potent anti-tumour activity with a favourable safety profile for patients with invasive cancers.

SLIDE TABLE
SLIDE TABLE
Program
MECHANISM OF ACTION
INDICATION
EARLY DISCOVERY
HIT TO LEAD
LEAD OPTIMIZATION
PRE-CLINICAL SAFETY
FIRST-IN HUMAN
Drug development programs
F2i
Inhibition of pro-invasive FGFR signalling
Gastric cancer
M4i
Inhibition of pro-invasive HGF signalling
Paediatric cancers
AKi
Inhibition of mitogenic regulators
Inhibition of mitogenic regulators
Novel targets
Non-kinase Target 1
Indirect inhibition of regulators of cytoskeleton dynamics
Carcinomas

TECHNOLOGY

ACINDA™: Anti-cancer cell invasion drug discovery accelerator

ACINDA consists of 3D tumouroid plates (3DT) plates (patent filed September 2018 and PCT filed in Dec 2019), proprietary cancer cell invasion models, automated cell dissemination counter (aCDc) software (proprietary) and computer-assisted drug designing (CADD) tools.

ACINDA is the first of its kind platform developed specifically for anti-cancer cell invasion drug discovery and it accelerates the ‘hit to lead’ phase of drug development by 50%.

ACINDA’s 3DT plates and cancer cell invasion models closely mimics the in vivo tumour micro environment and enables detailed analysis of signalling crosstalk, which leads to the identification of novel targets pertinent to caner cell invasion. Following the identification of these novel targets, first-in-class PPIAs are designed using ACINDA’s CADD tools. ACINDA’s aCDc software is the first fully automated software that quantifies cancer cell invasion at single cell resolution.

The efficacy, safety and mechanism of action of F2i have been extensively validated using various FGF-driven in vitro and in vivo models. F2i effectively inhibits tumour growth and invasion in different tumour xenograft models. F2i is currently in the 'lead optimisation' stage of drug development. 

FOUNDER

A dedicated management team

13 years of scientific development, four years of commercialization

Karthiga Kumar, PHD. MBA

Co-Founder, Chief Executive Officer, Chief Scientific Officer

Oncology-focused scientist with a keen interest in functional assay based personalised therapy, precision medicine and drug designing. 8+ years of hands-on experience in elucidating the mechanisms of cancer cell invasion and publications in leading peer-reviewed scientific journals. Responsible for product development and research and development at Invasight. Verve entrepreneur with an aspiration to build a company that develops advanced therapeutics for the better management of cancer, creating a positive difference in the lives of the patients with cancer.

BOARD OF DIRECTORS

Lorem ipsum dolor sit

Lorem ipsum dolor sit amet elit adipiscing consectetur adipisicing

John Doe

POSITION

John Doe

POSITION

John Doe

POSITION

John Doe

POSITION

John Doe

POSITION

SCIENTIFIC ADVISORY BOARD

Lorem ipsum dolor sit

Lorem ipsum dolor sit amet elit adipiscing consectetur adipisicing

John Doe

POSITION

John Doe

POSITION

John Doe

POSITION

John Doe

POSITION

John Doe

POSITION